Category: Clinical Breakthroughs
-
Statins Cost-Effective in Young Adults
Statin therapy has been shown cost-effective for lowering cholesterol in young adults, according to a study published in the Journal of the American College of Cardiology.
-
Predicting Which Glioblastoma Patients Will Respond to Immunotherapy
Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas — the most common and malignant of primary brain tumors — might benefit from immunotherapy.
-
Drug May Benefit Patients with Heart Failure
Dapagliflozin, a drug commonly used to treat type 2 diabetes, improved heart failure-related symptoms and physical limitations in patients with heart failure with preserved ejection fraction.
-
Identifying Cancer Biomarkers for Immunotherapy Response
Scientists have discovered a potential biomarker that could more accurately identify which patients with non-hypermutated cancers will respond to specialized immunotherapy drugs.
-
Drug May Improve Cardiac Function in Hypertrophic Cardiomyopathy
Valsartan, an angiotensin II receptor blocker drug, delayed disease progression and improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, according to a recent clinical trial.
-
New Drug Effective in Ulcerative Colitis
A new drug improved management of ulcerative colitis, according to a study published in NEJM.
-
One Coronavirus Vaccine May Protect Against Other Coronaviruses
Coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses, paving the way for future universal coronavirus vaccines.
-
For Every Man: Northwestern Investigators’ Critical Impact on Prostate Cancer
From teasing out determinants of health disparities to developing precision medicine treatments, clinicians and scientists from the Lurie Cancer Center are dramatically changing the landscape for all men with prostate cancer.
-
Advancing Treatment for B-cell Acute Lymphoblastic Leukemia
Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell immunotherapy, demonstrated safety and efficacy in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia, according to recent findings.
-
The Long Haul
The growing number of patients suffering from long-term complications of COVID-19 has spurred the creation of Northwestern Medicine’s Comprehensive COVID-19 Center, which provides coordinated, multidisciplinary care.
